AccessibilityHelpAbout Us
Umbra Companies logo

Umbra Companies(OTC) OCEL

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)-100%
5 Year-100%
1 Year-87%
1 Month+400%
N/A
Umbra Companies last closing stock price
MetricPriceDate
Last closeUSD 0.022026-09-16
Umbra Companies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+54.64%USD 0.012026-09-09
1 month+400%USD 0.002026-07-09
3 month+400%USD 0.002026-06-16
Year to date+400%USD 0.002025-12-31
1 year-86.55%USD 0.112025-09-11
3 year-99.5%USD 3.002023-08-25
5 year-99.7%USD 5.002021-07-29
Since inception-99.95%USD 30.002008-12-29

Umbra Companies Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.99M

Net Income (TTM)

-$3.88M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Apr 30, 2023

OCEL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Umbra Companies

Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical firm focused on developing biological therapies for degenerative conditions. The company’s primary investigational product, Zofin, is an acellular biological treatment derived from perinatal material, currently undergoing Phase I/II clinical evaluation for COVID-19.

Products and Services
  • Zofin: An acellular biological treatment for degenerative conditions
  • Educational and promotional solutions for healthcare sectors
  • Research collaborations with CDC and Oklahoma State University
Growth Outlook
  • Recent revenue growth of 78% from Q1 to Q2 2026
  • Strong gross profit margin of 79.6% in Q2 2026
  • Ongoing clinical trials may enhance market position and product pipeline
Financial Highlights
  • Q2 2026 revenue of $2.58 million, up from $1.45 million in Q1 2026
  • Operating loss reduced to $512,000 in Q2 2026 from $878,000 in Q1 2026
  • Cash and cash equivalents increased to $1.84 million in Q2 2026
Organicell Regenerative Medicine, Inc. is positioned in the biotechnology sector, focusing on innovative treatments that leverage biological materials. The company’s flagship product, Zofin, is being evaluated for its potential to address significant health challenges, including COVID-19. The recent financial performance indicates a positive trajectory, with substantial revenue growth and improved gross profit margins. The ongoing research collaborations with reputable institutions like the CDC and Oklahoma State University further enhance the company’s credibility and potential for future advancements. As the company continues to develop its product pipeline and expand its market presence, it may attract interest from investors looking for opportunities in the regenerative medicine space.
AI Generated • Sep 2, 2026

Industry

Electrical Equipment

Sector

Industrials

Employees

5

CEO

Rohn Monroe

Website

umbracompanies.com

Headquarters

Miami, FL 33140, US

OCEL Financials

Key Financial Metrics (TTM)

Gross Margin

81.52%

Operating Margin

-59.10%

Net Income Margin

-55.59%

Return on Equity

455.87%

Return on Capital

N/A

Return on Assets

-99.95%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$5.70M

Operating Income

-$4.13M

EBITDA

$77.00K

Operating Cash Flow

-$1.25M

Capital Expenditure

-$101.00K

Free Cash Flow

-$1.35M

Cash & ST Invst.

$1.85M

Total Debt

$96.00K

Umbra Companies Performance Analysis

Umbra Companies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Umbra Companies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-07-3113.7%
Q42025-10-3126.6%
Q12026-01-31-12.6%
Q22026-04-3078.5%
Umbra Companies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.00300.0%
20232023-12-31USD -0.00525.0%
20242024-12-31USD -0.00-44.0%
20252025-12-31USD -0.00-92.9%
Umbra Companies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-07-31-45.5%
Q42025-10-3162.5%
Q12026-01-31N/A
Q22026-04-3083.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$2.58M

+124.6%

Gross Profit

$2.06M

+130.1%

Gross Margin

79.62%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

20

N/A

Net Income

-$145.00K

+89.6%

EBITDA

$19.00K

+18.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.85M

+240.6%

Total Debt

$96.00K

-5.9%

Accounts Receivable

$276.00K

+2200.0%

Inventory

$686.00K

+191.9%

Long Term Debt

$63.00K

-23.2%

Short Term Debt

$33.00K

+65.0%

Return on Assets

-99.95%

N/A

Return on Invested Capital

-5.33%

N/A

Free Cash Flow

-$202.00K

-41.3%

Operating Cash Flow

-$138.00K

+3.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ATHJFAntisense Therapeutics Limited
$0.01-76.00%
AMHVAmerican Hemp Ventures, Inc.
$0.98+0.00%
VBIOValion Bio, Inc.
$2.08-1.42%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.61-0.03%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$103.97+1.61%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$50.11-1.94%
NOKNokia
$10.14+3.05%

Questions About OCEL

What is the current price of Umbra Companies?

Umbra Companies is trading at N/A per share.

What is the 52-week range for Umbra Companies?

Over the past 52 weeks, Umbra Companies has traded between N/A and N/A.

How much debt does Umbra Companies have?

As of the most recent reporting period, Umbra Companies reported total debt of $0.00.

How much cash does Umbra Companies have on hand?

Umbra Companies reported $53.13K in cash and cash equivalents in its most recent financial results.

What is Umbra Companies’s dividend yield?

Umbra Companies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services